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Objective: Chemoradiotherapy is a popular definitive therapy for esophageal carcinoma among many patients and
oncologists.Although the complete response rates are high and short-term survival is favorable after chemoradiother-
apy, persistent or recurrent locoregional disease is frequent. Salvage surgery is the sole curative intent treatment
option for this course of the disease. The present study evaluates the safety and value of salvage esophagectomy
for locoregional failure after high-dose definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Methods:We reviewed 59 consecutive patients with thoracic esophageal squamous cell carcinoma who under-
went salvage esophagectomy after definitive chemoradiotherapy. All patients received more than 60 Gy of radi-
ation plus concurrent chemotherapy for curative intent. The data were compared with those of patients who
received esophagectomy without preoperative therapy.
Results: Postoperative morbidity and mortality rates were increased among patients who underwent salvage
esophagectomy compared with those who underwent esophagectomy without preoperative therapy (mean hospi-
tal stay, 38 vs 33 days; anastomotic leak rates, 31% vs 25%; respiratory complication rates, 31% vs 20%; re-
intubation within 1 week, 2% vs 2%; hospital mortality rates, 8% vs 2%). Tracheobronchial necrosis and
gastric conduit necrosis were highly lethal complications after salvage esophagectomy; 3-year postoperative
survivals were 38% and 58%, respectively.
Conclusion: Patients who underwent salvage esophagectomy after definitive high-dose chemoradiotherapy
had increased morbidity and mortality. Nevertheless, this is acceptable in view of the potential long-term survival
after salvage esophagectomy. Such treatment should be considered for carefully selected patients at specialized
centers.Surgical resection has been the standard treatment for local-
ized esophageal squamous cell and adenocarcinoma for sev-
eral decades. Despite many efforts to improve surgical
resection, the associated mortality and morbidity rates re-
main high and the postoperative quality of life is unsatisfac-
tory. Management algorithms for patients with esophageal
carcinoma have changed during the last 2 decades. Multidis-
ciplinary approaches have included surgery, radiotherapy,
and chemotherapy, alone or in combination. The Radiation
Therapy Oncology Group trial (RTOG 85-01), which added
chemotherapy to radiotherapy for resectable esophageal car-
cinoma, has established chemoradiotherapy (CRT) without
surgery as one standard for definitive treatment.1,2 Many
patients and oncologists have accepted the nonsurgical
approach with CRT as definitive therapy for esophageal
carcinoma. Evaluations of consecutive patients with esoph-
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the American College of Surgeons have shown that radiation
combined with chemotherapy is the most frequent treatment
strategy for all stages of squamous cell carcinoma in the
United States.3
Although complete response (CR) rates are high and
short-term survival is favorable after definitive CRT, locore-
gional disease persists or recurs in 40% to 60% of patients.4
The only curative intent treatment option for locoregional re-
lapse is salvage surgery.5 Such patients are at increased risk
for esophagectomy because they have been treated with
higher doses of radiation and the treatment is usually com-
pleted months beforehand.6
The present study evaluates the safety and efficacy of sal-
vage esophagectomy for locoregional failure after high-dose
definitive CRT for esophageal squamous cell carcinoma.We
retrospectively reviewed all patients who underwent esoph-
ageal resection between 2000 and 2006 at the National Can-
cer Center Hospital and selected all patients undergoing
salvage esophagectomy after failed definitive CRT (n ¼
59). We compared the data with those of patients treated
by esophagectomy without preoperative therapy during the
same period (n ¼ 553).
MATERIALS AND METHODS
We reviewed 59 consecutive patients with thoracic esophageal squamous
cell carcinoma who underwent salvage esophagectomy after high-doseCardiovascular Surgery c Volume 137, Number 1 49
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definitive CRT between 2000 and 2006 at the National Cancer Center
Hospital, Tokyo. All selected patients had received more than 60 Gy of ex-
ternal beam radiation as high-dose definitive CRT without planned surgery.
The chemotherapeutic regimens for these patients predominantly comprised
5-fluorouracil and cisplatin concurrently with radiation therapy. These pa-
tients included 22whowere initially treated at other hospitals with definitive
CRT and who were admitted to the National Cancer Center Hospital after
the primary tumor relapsed. We reviewed the other hospital records of these
patients to confirm treatment details. Assessments of these patients indicated
that 23 had achieved CR after CRT, but disease relapsed later. The remain-
ing 36 patients had not achieved CR and underwent salvage surgery for
residual tumors.
The data were compared with those of 553 patients who underwent
planned esophagectomy without preoperative therapy during the same pe-
riod. Long-term outcomes, encompassing overall survival, were obtained
from hospital records and the tumor registry. Overall survival was calcu-
lated from the day of surgery until death or was censored at the time last
known to be alive.
Data were statistically analyzed using the Pearson chi-square test or the
Fisher exact test as appropriate. Kaplan–Meier survival curves were esti-
mated with differences based on patient characteristics assessed by the
log-rank test to compare the distribution of survival. Survival of the 54 pa-
tients who underwent salvage esophagectomy after CRT, excluding perio-
perative deaths, was examined using univariate and multivariable analyses.
RESULTS
Table 1 compares the clinical characteristics of patients
who underwent salvage esophagectomy after CRT (salvage
group) with who did not receive preoperative therapy. The
salvage group contained more male patients and less ad-
vanced pathologic stages, but age and tumor location did
not significantly differ. Of 7 patients with no pathologically
residual tumors (pT0) in the resected esophagus, analysis of
preoperative endoscopic biopsy revealed that 2 had tumor
cells. Another 5 patients had stenosis and ulcers with a thick-
ened wall according to computed tomography examinations
suggesting recurrence. All patients with M1 had lymph node
metastasis in the neck or celiac area. These patients were in-
dicated for 3-field dissections at the National Cancer Center
Hospital.7 Patients with distant organ metastasis were not
candidates for esophagectomy.
Table 2 compares the surgical procedures and results
between the 2 groups. Surgical procedures significantly
differed, such as in the extent of lymphadenectomy and
reconstruction route. The salvage group tended to have
fewer cervical anastomoses (75% vs 96%), reflecting
a lower proportion of 3-field lymph node dissections
(41% vs 91%). Anastomotic techniques in both groups
were similar: Neck anastomosis was performed with the sin-
gle-layer interrupted hand suture technique, and thoracic50 The Journal of Thoracic and Cardiovascular Suranastomosis was performed with the stapling technique.
The rate of noncurative surgery (R1, R2) tended to be
more frequent in the salvage group (15% vs 9%), but the
difference did not reach statistical significance.
Postoperative morbidity and mortality rates were in-
creased in the salvage group compared with those who did
not receive preoperative therapy (Table 3). The salvage
group had more respiratory complications (32% vs 20%),
including more empyema, mediastinitis, and tracheobron-
chial necrosis. Tracheobronchial necrosis developed in 4
patients in the salvage group. Tracheobronchial necrosis
without anastomotic leak in the neck developed in 2 patients;
1 patient died and 1 patient survived after an omental patch
was grafted onto the tracheobronchial fistula. All patients in
both groups were extubated in the operating room immedi-
ately after surgery. The ratio of those requiring reintubation
and ventilation within 1 week after surgery was not in-
creased in the salvage group (2% vs 2%), whereas rates
of anastomotic leakage (31% vs 25%) and wound infection
TABLE 1. Clinical characteristics and pathologic factors
Salvage after
CRT n ¼ 59
No preoperative
therapy n ¼ 553 P value
Gender (No.)
Male 57 (97%) 483 (87%) .0330
Female 2 (3%) 70 (13%)
Age (y)
Median 63 62 .0821
Range 34–75 41–83
Location
Upper 13 (22%) 88 (16%) .4839
Middle 26 (44%) 261 (47%)
Lower 20 (34%) 204 (37%)
pT
pT0 7 (12%)
pT1 11 (19%) 176 (32%) <.0001
pT2 5 (8%) 62 (11%)
pT3 30 (51%) 277 (50%)
pT4 6 (10%) 38 (7%)
pN
pN0 38 (64%) 161 (29%) <.0001
pN1 21 (36%) 392 (71%)
pM
pM0 52 (88%) 440 (80%) .1238
pM1 lym 7 (12%) 113 (20%)
pStage
pStage 0 6 (10%) .0006
pStage I 5 (9%) 93 (17%)
pStage IIA 20 (34%) 58 (11%)
pStage IIB 5 (9%) 100 (18%)
pStage III 16 (27%) 189 (34%)
pStage IVA 2 (3%) 19 (5%)
pStage IVB 5 (9%) 84 (15%)
CRT, Chemoradiotherapy.
M1 lym had lymph node metastasis in the neck or in the celiac area.gery c January 2009
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Mean hospital stay (38 vs 33 days) tended to be increased
in the salvage group in parallel with increased postoperative
morbidity. The hospital mortality rate (8% vs 2%) was sig-
nificantly increased in the salvage group. Table 4 lists the
causes of postoperative hospital mortality. A reconstruction
via the anterior mediastinum with cervical anastomosis is
our standard procedure. One patient died of tracheobron-
TABLE 2. Surgical factors
Salvage after
CRT n ¼ 59
No preoperative
therapy n ¼ 553 P value
Resection approach
Right thoracotomy 56 (95%) 539 (97%) .2740
Left thoracotomy 3 (1%)
Transhiatal 3 (5%) 11 (2%)
Lymph node dissection
3-field 24 (41%) 504 (91%) <.0001
Others 35 (59%) 49 (9%)
Reconstruction conduit
Stomach 56 (95%) 506 (92%) .6931
Colon 3 (5%) 42 (8%)
Jejunum 2 (.4%)
Reconstruction route
Anterior 26 (44%) 404 (73%) <.0001
Posterior 31 (53%) 132 (24%)
Subcutaneous 2 (3%) 17 (3%)
Anastomosis
Cervical 44 (75%) 530 (96%) <.0001
Thoracic 13 (22%) 17 (3%)
Subcutaneous 2 (3%) 6 (1%)
Curability
R0 50 (85%) 505 (91%) .1018
R1, R2 9 (15%) 48 (9%)
CRT, Chemoradiotherapy.
TABLE 3. Postoperative morbidity and mortality
Salvage after
CRT n ¼ 59
No preoperative
therapy n ¼ 553
P
value
Respiratory complication 19 (32%) 113 (20%) .0452
Pneumonia 6 (10%) 46 (8%)
Empyema and
mediastinitis
7 (12%) 27 (5%)
Tracheobronchial
necrosis
4 (7%) 1 (.2%)
Recurrent nerve paralysis 11 (19%) 127 (23%) .3396
Ventilation within 1 wk 1 (2%) 10 (2%) >.9999
Tracheotomy 2 (3%) 6 (1%)
Anastomotic leak 18 (31%) 138 (25%) .0034
Conduit necrosis 2 (3%) 1 (.2%)
Wound infection 16 (27%) 83 (15%) .0163
Hospital stay (d) 38.3  35.1 31.2  33.8 .1279
Hospital mortality 5 (8%) 10 (2%) .0099
Operative mortality 1 (.2%)
CRT, Chemoradiotherapy.The Journal of Thoracic andchial necrosis without anastomotic leak in the neck. A leak
into the posterior mediastinum developed in 1 patient, caus-
ing mediastinitis and tracheobronchial necrosis; this patient
survived after an omental patch was grafted onto the tracheo-
bronchial fistula. A leak and fatal bleeding from the carotid
artery developed in 1 patient. After these events, the recon-
struction route was changed to the posterior mediastinum
with intrathoracic anastomosis and omental cover onto the
tracheobronchus. However, gastric conduit necrosis in the
posterior mediastinum caused mediastinitis and tracheo-
bronchial necrosis in 2 patients. After these events, the
reconstruction route was returned again to the anterior medi-
astinum with cervical anastomosis. Neck dissection was
canceled in the salvage group, in contrast with the other
group who underwent 3-field dissection as a standard proce-
dure. One patient died of interstitial pneumonitis and cardiac
failure, which were presumed to have been caused by late
toxicity of CRT. Three patients in the salvage group died
of respiratory failure and cardiac failure, which were pre-
sumed to have been caused by late toxicity of CRT, more
than 12 months after salvage surgery.
According to differences in operative morbidity and
mortality, overall survival was significantly better in the
group who received no preoperative therapy (Figure 1).
TABLE 4. Causes of postoperative hospital mortality
Salvage after
CRT n ¼ 59
No preoperative
therapy n ¼ 553
Tracheobronchial necrosis 1 (2%)
Conduit necrosis and
tracheobronchial necrosis
2 (3%) 1 (0.2%)
Leakage and arterial bleeding 1 (2%) 1 (0.2%)
Radiation pneumonitis and
cardiac failure
1 (2%)
Pneumonia 3 (0.5%)
Leakage and mediastinitis 5 (0.9%)
CRT, Chemoradiotherapy.
FIGURE 1. Overall survival curves of patients undergoing salvage esoph-
agectomy after definitive CRT (n ¼ 59) or no preoperative therapy (n ¼
553). CRT, Chemoradiotherapy.Cardiovascular Surgery c Volume 137, Number 1 51
General Thoracic Surgery Tachimori et al
G
T
SThree-year postoperative survivals were 37.8% in the sal-
vage group and 60.8% in the group without preoperative
therapy.
We evaluated the factors associated with long-term sur-
vival after salvage esophagectomy in the 54 patients who
survived the perioperative period. Univariate analysis re-
vealed no associations between increased survival and any
of gender, age (<60 or 60 years), tumor location, CRT re-
sponse (recurrence after CR or non-CR; Figure 2), time from
CRT to salvage esophagectomy (12 or>12 months), or
pathologic N and M factors (Table 5). Pathologic T factor
(T1-3 or T4) and R0 resection (R0 or R1-2) were associated
with increased survival (Figures 3 and 4). Patients with path-
ologic T4 and those with noncurative resection (R1-2)
closely overlapped. Of 6 patients with pathologic T4 tumors,
R0 resection was performed in only 1 patient via combined
resection of the pericardium. Noncurative resection was also
completed in 2 patients with peritoneal dissemination and in
FIGURE 2. Overall survival curves of patients undergoing salvage esoph-
agectomy (n ¼ 54) according to CRT response (excluding perioperative
deaths, n ¼ 5). CR, Complete response.
TABLE 5. Univariate and multivariate analyses of salvage
esophagectomy long-term survival
UnivariateMultivariate
Characteristics P value HR 95% CI P value
Gender (F/M) .9288 1.574 0.168–14.710 .6910
Age (60 y/<60 y) .8989 3.471 0.997–12.084 .0505
Location (upper/lower) .5313 1.114 0.228–5.436 .8942
(middle/lower) .1773 1.884 0.578–6.140 .2934
CRT response (recurrence
after CR/non-CR)
.6371 0.786 0.212–2.918 .7188
Time from CRT to salvage
(12 mo/>12 mo)
.5534 1.460 0.454–4.698 .5256
pT (T1–3/T4) <.0001 0.047 0.006–0.364 .0034
pN (N0/N1) .1517 0.522 0.203–1.342 .1772
pM (M0/M1-lym) .0694 0.128 0.030–0.557 .0061
R (R0/R1-2) <.0001 0.421 0.070–2.522 .3437
HR, Hazard ratio; CI, confidence interval; CRT, chemoradiotherapy; CR, complete re-
sponse.52 The Journal of Thoracic and Cardiovascular Surg1 patient with extended node metastasis. The most signifi-
cant factor associated with increased survival seemed to be
R0 resection.
DISCUSSION
In contrast with Western countries, where the rate of ade-
nocarcinoma is increasing, squamous cell carcinoma persists
among most Japanese patients with esophageal cancer.8,9
The landmark RTOG 85-01 randomized trials have clearly
demonstrated that CRT is a curative approach for squamous
cell carcinoma.1,2 Medical and radiation oncologists have re-
ported improved survival of patients with esophageal cancer
treated by definitive CRT without surgery.10-13 Definitive
CRT without planned surgery has been offered to patients
with potentially resectable esophageal tumors in many
Japanese institutions during the past decade.14 During the
period of this analysis, 480 patients received definitive
FIGURE 3. Overall survival curves of patients undergoing salvage esoph-
agectomy (n ¼ 54) according to pathologic T factor (excluding periopera-
tive deaths, n ¼ 5).
FIGURE 4. Overall survival curves of patients undergoing salvage esoph-
agectomy (n ¼ 54) according to R classification (excluding perioperative
deaths, n ¼ 5).ery c January 2009
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squamous cell carcinoma in our institution.
The phase III randomized controlled trial, INT 0123
(RTOG 9405), found no improvement in survival in dose
comparisons of high-dose (64.8 Gy) versus standard-dose
(50.4 Gy) radiation and the effect on locoregional control
did not improve.15 Thus, the standard radiation dose for
definitive CRT has become 50 to 50.4 Gy in the United
States. Definitive CRT has mostly comprised combinations
with a conventional radiation dose of more than 60 Gy in
Japan.10-13 Clinical trials for definitive CRT at a dose of
50.4 Gy are ongoing. All patients analyzed in the present
study were dosed with more than 60 Gy of external beam
radiation as definitive CRT.
Before and during the period of this analysis, 2 consecu-
tive phase III randomized controlled trials at the National
Cancer Center Hospital compared the outcomes of postoper-
ative chemotherapy with surgery alone (JCOG9208)16 and
postoperative chemotherapy with preoperative chemother-
apy (JCOG9907) for surgical patients. Less than 10 surgical
candidates received the preoperative CRT, and 45 patients
received preoperative chemotherapy. Patients who received
no preoperative treatment, including surgery alone or sur-
gery with postoperative chemotherapy, comprised the con-
trol group for analysis in the present study.
The morbidity and mortality rates of patients who under-
went salvage esophagectomy after CRT increased because
of the effects of the radiation administered to the mediasti-
num and the tissues used as conduits.17 Higher doses of ra-
diation are associated with increased morbidity,18,19 and
irradiation of the esophagus and stomach might affect the
blood supply, which might contribute to leakage. Gastric
conduit necrosis in the posterior mediastinum caused mortal
mediastinitis in 2 patients, necessitating surgical modifica-
tions to reduce the impact of leaks into the thoracic cavity.
The reconstruction route was changed to the anterior medi-
astinum with cervical anastomosis.
Ischemic tracheobronchial lesions are serious complica-
tions of esophagectomy with extensive lymph node dissec-
tion, particularly in patients undergoing preoperative
CRT.20 Four patients in the salvage group developed tra-
cheobronchial necrosis, of which 3 of them died. The re-
maining patient who received an omental patch graft
survived. Protective measures to prevent ischemic tracheo-
bronchial lesions include, in addition to careful dissection
around the airway, preservation of the bronchial arteries dur-
ing resection.21 We changed our salvage esophagectomy
procedure to preserve the right posterior bronchial artery.
Neck dissection was also avoided to preserve the blood sup-
ply from the inferior thyroidal artery to the trachea. Al-
though our standard surgery for esophageal cancer is right
thoracotomy and 3-field dissection, the extent of lymphade-
nectomy was reduced in salvage esophagectomy because of
high operative risk.The Journal of Thoracic andThe incidence of acute toxicity of CRT seemed to be sub-
stantial. However, long-term or late cardiopulmonary toxic-
ity cannot be ignored in patients who survive after CRT22,23
or in those who undergo salvage esophagectomy after CRT.
One patient in the salvage group died of interstitial pneumo-
nitis and cardiac failure postoperatively, which were suppos-
edly caused by late toxicity of CRT. In addition, 3 patients
died of respiratory failure and cardiac failure more than 12
months after salvage surgery. A strategy to minimize the
normal tissue toxicity of CRT should be identified.
We reviewed several factors to identify which subset of
patients derived a benefit from salvage esophagectomy. Uni-
variate analysis revealed that T1-3 and R0 were significant
factors. The most significant factor associated with long-
term survival seemed to be R0 resection.24,25 Fibrosis is usu-
ally promoted in radiation fields, and some cancer cells are
likely to be left behind in the deep layer of the esophageal
wall after radiotherapy. Therefore, to accurately evaluate
the T factor of irradiated patients might be difficult preoper-
atively, and irradiated tissues are difficult to distinguish from
tumors during surgery.
CONCLUSIONS
Patients who underwent salvage esophagectomy after de-
finitive high-dose CRT had higher morbidity and mortality
rates that patients undergoing esophagectomy without pre-
operative therapy. Nevertheless, this is the only established
treatment strategy that offers any chance of long-term sur-
vival. This morbidity rate is acceptable in view of the poten-
tial for long-term survival after salvage esophagectomy.
Patients should be carefully selected for salvage esophagec-
tomy after high-dose CRT at referral centers that specialize
in esophageal cancers.
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